Company
Headquarters: Lysaker, Norway
Employees: 551
kr7.87 Billion
NOK as of July 1, 2024
US$738.8 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates in two segments, Ingredients and Brands. The company provides krill oil products, including omega-3s, phospholipids, choline, and astaxanthin under the Superba, Kori, NKO, and K·REAL brands. It also offers Qrill aqua nutrient-rich feed ingredients for aquaculture; and QRILL pet, a functional ingredient for pet food. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste into products, such as shopping baskets and food trays. Aker BioMarine AS has an agreement with Medical Food Solutions Research to develop pharmaceutical therapies for brain and eye health based on Lysoveta. The company is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Aker BioMarine AS has the following listings and related stock indices.
Stock: OSE: AKBM wb_incandescent
Stock: Munich: 1PG wb_incandescent